Obesity: New life for antidiabetic drugs
New life for antidiabetic drugs
Antidiabetic drugs that activate the protein PPARγ had a bright start but soon lost their appeal because of undesirable side effects. Subtle modifications may once again make them suitable for treating diabetes.
Prof. Johan Auwerx and Dr. Riekelt H. Houtkooper (LISP - Laboratory of Integrative and Systems Physiology) discuss how subtle modifications to antidiabetic drugs that activate the protein PPARgamma may once again make them suitable for treating diabetes by avoiding their undesirable side effects.